MarketPulse

myasthenia gravis

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kyverna's Miv-cel Shows Durable Benefits in Stiff Person Syndrome Trial

Kyverna's miv-cel shows statistically significant benefits across all endpoints in stiff person syndrome trial, with 81% achieving meaningful walking speed improvement.
KYTXclinical trialautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx Expands VYVGART Leadership with Positive Phase 3 Data Across MG and CIDP

argenx presents Phase 3 data supporting VYVGART expansion across ocular MG, seronegative MG, and treatment-naïve CIDP, with 87.5% early benefit rates.
ARGXFDA approvalPhase 3 trials